Clinical Characteristics of NOPR Cohorts
| Restaging or suspected recurrence | ||||||
| Age < 65 y | Age > 65 y | Chemotherapy monitoring, all ages | ||||
| NOPR interval cohort | 2006* | 2009* | 2006 | 2009 | 2006 | 2009 |
| Patients (n) | 3,051 | 5,916 | 26,551 | 46,682 | 10,234 | 15,611 |
| Age (y) | ||||||
| Mean | 53.7 | 55.0 | 74.9 | 75.1 | 72.3 | 72.2 |
| 25%–75% range | 49–61 | 51–62 | 70–79 | 70–80 | 68–78 | 68–78 |
| Eastern Cooperative Oncology Group Performance Status | ||||||
| Asymptomatic; performance status = 0 (%) | 986 (32.3) | 2,107 (35.6) | 10,433 (39.3) | 18,290 (39.2) | 2,197 (21.5) | 2,929 (18.8) |
| Symptomatic, fully ambulatory; performance status = 1 (%) | 1,601 (52.5) | 3,108 (52.5) | 12,835 (48.3) | 23,213 (49.7) | 6,226 (60.8) | 9,996 (64.0) |
| Performance status = 2, 3, or 4 (%) | 464 (15.2) | 701 (11.8) | 3,283 (12.4) | 5,179 (11.1) | 1,811 (17.7) | 2,686 (17.2) |
| Summary stage† | ||||||
| No or low probability of disease recurrence | 1,568 (51.4) | 3,190 (53.9) | 12,283 (46.3) | 21,834 (46.8) | 1,514 (14.8) | 2,179 (14.0) |
| Local or nodal recurrence | 392 (12.8) | 651 (11.0) | 3,546 (13.4) | 5,793 (12.4) | 1,332 (13.0) | 1,736 (11.1) |
| Metastatic disease | 1,091 (35.8) | 2,075 (35.1) | 10,721 (40.4) | 19,055 (40.8) | 6,431 (62.8) | 10,323 (66.1) |
| Stage unknown | – | – | – | – | 957 (9.4) | 1,373 (8.8) |